Marshall Wace’s PTC Therapeutics PTCT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $57.5M | Buy |
704,787
+244,149
| +53% | +$17.6M | 0.05% | 327 |
|
|
2026
Q1 | $31.4M | Buy |
460,638
+212,892
| +86% | +$15.1M | 0.03% | 540 |
|
|
2025
Q4 | $18.8M | Buy |
247,746
+90,007
| +57% | +$6.54M | 0.02% | 650 |
|
|
2025
Q3 | $9.68M | Sell |
157,739
-380,037
| -71% | -$19.8M | 0.01% | 926 |
|
|
2025
Q2 | $26.3M | Sell |
537,776
-203,226
| -27% | -$9.65M | 0.03% | 489 |
|
|
2025
Q1 | $37.8M | Buy |
+741,002
| New | +$37M | 0.05% | 345 |
|
|
2024
Q3 | – | Sell |
-179,679
| Closed | -$5.49M | – | 2873 |
|
|
2024
Q2 | $5.49M | Buy |
179,679
+157,460
| +709% | +$5.1M | 0.01% | 959 |
|
|
2024
Q1 | $646K | Buy |
+22,219
| New | +$622K | ﹤0.01% | 1835 |
|
|
2023
Q3 | – | Sell |
-6,182
| Closed | -$251K | – | 2579 |
|
|
2023
Q2 | $251K | Buy |
+6,182
| New | +$302K | ﹤0.01% | 2185 |
|
|
2022
Q1 | – | Sell |
-6,042
| Closed | -$241K | – | 3884 |
|
|
2021
Q4 | $241K | Hold |
6,042
| – | – | ﹤0.01% | 3102 |
|
|
2021
Q3 | $225K | Hold |
6,042
| – | – | ﹤0.01% | 2763 |
|
|
2021
Q2 | $255K | Sell |
6,042
-36,215
| -86% | -$1.55M | ﹤0.01% | 2378 |
|
|
2021
Q1 | $2M | Buy |
+42,257
| New | +$2.51M | 0.01% | 1326 |
|
|
2020
Q4 | – | Sell |
-29,800
| Closed | -$1.39M | – | 2113 |
|
|
2020
Q3 | $1.39M | Sell |
29,800
-4,776
| -14% | -$235K | 0.01% | 906 |
|
|
2020
Q2 | $1.75M | Buy |
+34,576
| New | +$1.7M | 0.01% | 833 |
|
|
2020
Q1 | – | Sell |
-26,615
| Closed | -$1.28M | – | 1982 |
|
|
2019
Q4 | $1.28M | Sell |
26,615
-207,941
| -89% | -$8.84M | 0.01% | 925 |
|
|
2019
Q3 | $7.93M | Buy |
+234,556
| New | +$10.2M | 0.06% | 359 |
|
|
2019
Q1 | – | Sell |
-25,632
| Closed | -$880K | – | 1998 |
|
|
2018
Q4 | $880K | Buy |
+25,632
| New | +$922K | 0.01% | 946 |
|
|
2018
Q3 | – | Sell |
-20,278
| Closed | -$684K | – | 1255 |
|
|
2018
Q2 | $684K | Buy |
+20,278
| New | +$632K | 0.01% | 547 |
|
|
2016
Q1 | – | Sell |
-44,410
| Closed | -$1.44M | – | 1160 |
|
|
2015
Q4 | $1.44M | Buy |
44,410
+14,926
| +51% | +$439K | 0.01% | 629 |
|
|
2015
Q3 | $787K | Buy |
29,484
+12,009
| +69% | +$514K | 0.01% | 665 |
|
|
2015
Q2 | $841K | Sell |
17,475
-3,620
| -17% | -$211K | 0.01% | 626 |
|
|
2015
Q1 | $1.28M | Buy |
21,095
+278
| +1% | +$17K | 0.02% | 535 |
|
|
2014
Q4 | $1.08M | Buy |
20,817
+13,186
| +173% | +$580K | 0.01% | 553 |
|
|
2014
Q3 | $336K | Buy |
+7,631
| New | +$239K | ﹤0.01% | 692 |
|
Other funds holding PTCT
RI
JT
Marshall Wace's PTCT Position: Q2 2026 in Review
Marshall Wace increased its PTC Therapeutics (PTCT) stake by 53% in Q2 2026, buying an estimated $17.6M and bringing the position to 704,787 shares worth $57.5M. The position accounts for 0.05% of the portfolio, ranked #327.
Marshall Wace first reported a position in PTCT in Q3 2014 and has held it in 25 quarters since. 382 funds tracked by Wall St. Rank hold PTCT as of Q2 2026.
- Marshall Wace held 704,787 shares of PTC Therapeutics worth $57.5M as of Q2 2026.
- Marshall Wace bought 244,149 PTC Therapeutics shares in Q2 2026, an estimated $17.6M.
- PTC Therapeutics made up 0.05% of Marshall Wace's portfolio in Q2 2026, its #327 holding.
- Marshall Wace first reported a position in PTC Therapeutics in Q3 2014 and has held it in 25 quarters since.
- 382 funds tracked by Wall St. Rank held PTC Therapeutics as of Q2 2026.
Based on Marshall Wace's 13F filing for Q2 2026, filed 13 Aug 2026.